Fortress Biotech Q1 net income turns to $137.16 million; revenue rises 22% to $16.04 million

• Fortress Biotech posted net income of USD 137.16 million for quarter ended March 31, 2026, swinging from a loss year earlier, while revenue rose 22% to USD 16.04 million.
• Operating loss narrowed 65% to USD 7.74 million, as total operating expenses fell 33% to USD 23.78 million.
• Other income jumped to USD 150.03 million, driven by a USD 158.87 million gain on Cyprium sale of a priority review voucher.
• Cash and cash equivalents totaled USD 255.8 million at March 31, 2026, while net cash provided by operating activities was USD 203.85 million.
• Journey reported Emrosi access expanded to about 85% of US commercial lives, while Cyprium said FDA approved ZYCUBO for Menkes disease in pediatric patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fortress Biotech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-061233), on May 14, 2026, and is solely responsible for the information contained therein.